 |
|
|
| |
Strong intrahepatic decline of hepatitis D virus RNA and antigen after 48 weeks of treatment with Bulevirtide in chronic HBV/HDV co-infected patients: Interim results from a multicenter, open-label, randomized phase 3 clinical trial (MYR301)
|
| |
| |
AASLD 2021 Nov 12-15
Lena Allweiss, Annika Volmari, Yvonne Ladiges, Corinna Eggers, Katja Giersch, Katrin Schoneweis, Vithika Suri, Jeffrey Wallin, Heiner Wedemeyer, Stephan Urban, Marc Lütgehetmann, Jan-Hendrik Bockmann, Maura Dandri
|
| |
|
|
|
|
|
